JPRN-jRCTs041190055已完成4 期
A Clinical Study of Carglumic Acid in Patients with Late-Onset Ornithine Transcarbamylase Deficiency
Ito Tetsuya0 个研究点目标入组 2 人开始时间: 2019年7月24日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 2
研究概览
简要总结
In one case, the administration of calglumic acid decreased the blood glutamine level and stabilized the ammonia level during the administration period, but in the other case, no significant change was observed. In this study, the clear therapeutic effect was not observed. Since the clinical severity and genotype of the two cases were different, our data indicate that the effect of calglumate may depend on their severity of residual activity and can be effective in some cases.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 < 75age old（—）
- 性别
- All
入选标准
- •1. Chronic phase patients with genetically diagnosed ornitine transcarbamylase (OTC) deficiency.
- •2. Patients with the blood ammonia levels>60ug/dL(neonate:>200ug/dL, infant:>100ug/dL) under the treatment with Low-protain daiet, phenylbutyrate and citrurine administration. Or patients whoes blood ammonia level was two times higher than the average of before 6 months at outpatients clinic.
- •3. Male and female, below 75 years old at informed concent is obtained.
- •4. Patients who obtained written informed consent form the patient or legal representative.
排除标准
- •1. Other types of urea cycle disorders or patients with organic acidemias.
- •2. Hyperammonemia due to acquired amino acid metabolism abnormality such as vilal hepatites, port-systemic shunt, biliary atresia or hepatic failure.
- •3. Completely defected patients of OTC activity.
- •4. Liver transplanted patients.
- •5. Patients who reseved dialysis within two days before the treatment.
- •6. Past histry of symptomatic worsening after drug administration, occurrence of adverse event or hypersensitivity.
- •7. Patients with severe hepatic, renal or cardiac disease
- •8. Patients who is pregnant or may be pregnant, or lactating.
- •9. Patients with drug hypersensitivity.
- •10. Patients who are involved in other clinical trials or had been involved within the last 3 months.
- •11. Patients who are determined as disqualified by attending physician.
研究者
相似试验
Unknown
2 期
N-Carbamylglutamate (Carbaglu) In The Treatment Of HyperammonemiaInborn Errors of MetabolismNCT00843921Mendel Tuchman52
已完成
3 期
Oral Glutamine in the Prevention of Oxaliplatin-induced NeurotoxicityColorectal NeoplasmsNCT01087658Sanofi200
已完成
1 期
A Clinical Study of Alanyl-Glutamine for Reduction of Post-Myomectomy AdhesionsPelvic AdhesionsNCT01701193Temple Therapeutics BV47
已完成
1 期
se of a substance to prevent and control mouth inflammation caused by radiotherapyStomatitisRBR-9yrnbgniversidade Estadual da Paraíba
终止
2 期
Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile InfectionClostridium Difficile InfectionNCT02053350University of Virginia7